Becton, Dickinson and Company (BDX) Stock: Price, Forecast & Analyst Target
Becton, Dickinson and Company (BDX) — MoonshotScore 68/100 (Strong band), calculated Nov 18, 2026. Price $212.78 (+0.05%), as of the Nov 20, 2026 trading session; market cap $58.0B. Expected results Feb 8, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Becton, Dickinson and Company · BDX · NYSE · Healthcare · Medical - Instruments & Supplies
Research dated 2026-09-12 (results through Q3 FY2026; Q4 FY2026 not covered): Becton, Dickinson sells the tools that move medication, collect and analyze specimens, and support surgical or vascular procedures across hospitals, laboratories, researchers, and pharmaceutical manufacturers. The case rests on whether the latest profit recovery can endure while cash remains modest beside debt and reported revenue continues to move unevenly.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Becton, Dickinson and Company (BDX)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, but a strained balance sheet, weak growth and a full valuation; the market is already moving on it. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Fading; Momentum: Surging.
- quarterly revenue $5.27B (Q4 FY2026, quarter ended Sep 2026)
- EPS beat 8 of the last 8 reports
- expected results Feb 8, 2027
Holding back: soft growth
Helping: business quality, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 67 | Strong | |
| 67 | Strong | |
| 67 | Strong | |
| 68 | Strong | |
| 68 | Strong | |
| 68 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $212.78 | |
| Change on the day | +0.05% | |
| 52-week range | $140.11–$220.36 | |
| Market capitalisation | $58.0B | — |
| Price / earnings (trailing) | 51.91 | |
| Shares traded on the day | 1.94M | |
| Beta (volatility vs the S&P 500) | 0.28 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Becton, Dickinson and Company (BDX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Becton, Dickinson and Company (BDX), and what does it report?
Short answer · as of
BD is not mainly a maker of occasional big-ticket medical machines.
Research dated 2026-09-12 (results through Q3 FY2026; Q4 FY2026 not covered).
Its portfolio reaches into routine clinical work through syringes, needles, catheters, specimen collection products, diagnostic assays, laboratory systems, medication dispensing, infusion therapy, surgical repair, and interventional devices.
Reported revenue combines distinct demand streams. Medical is the largest segment and centers on medication delivery and management; Life Sciences serves diagnostic and research workflows; Interventional depends more directly on surgical, vascular, urology, and critical-care procedures. Consolidated growth therefore measures a blend of everyday supplies, laboratory activity, system demand, and procedure volumes.
What do the latest results show for Becton, Dickinson and Company (BDX)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $5.27B.
Research dated 2026-09-12 (results through Q3 FY2026; Q4 FY2026 not covered).
The latest quarter brought a rebound from the preceding period: revenue, gross profit, operating profit, net income, and diluted earnings all improved, with the business returning to profitability. Revenue and per-share earnings also exceeded estimates, extending a pattern in which reported per-share results have cleared expectations even when revenue has not always done so.
The mechanical bridge is operating leverage rather than revenue alone. A comparatively modest sales recovery coincided with a much larger rise in operating profit as gross profit strengthened and selling, general, and administrative expense increased only slightly. The annual record is less clean: sales expanded while net income slipped, so recent profit improvement has not yet established a durable earnings trend.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
| Sep 30, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $5.27B Nov 5, 2026
- Latest report · revenue estimate
- $5.11B Nov 5, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 5, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 5, 2026 | $5.27B | $5.11B | $4.1500 | $4.0700 |
| Aug 6, 2026 | $4.98B | $4.89B | $3.2300 | $3.1400 |
| May 7, 2026 | $4.71B | $4.67B | $2.9000 | $2.7800 |
| Feb 9, 2026 | $4.49B | $5.15B | $2.2900 | $2.2100 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $5.27B | $696M | $2.54 (diluted) |
| Q3 FY2026 | $4.98B | $377M | $1.37 (diluted) |
| Q2 FY2026 | $4.71B | -$311M | -$1.11 (diluted) |
| Q1 FY2026 | $5.25B | $382M | $1.34 (diluted) |
What are the financial strengths and risks for Becton, Dickinson and Company (BDX)?
Short answer · as of
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12 (results through Q3 FY2026; Q4 FY2026 not covered).
BD continues to generate operating cash, and capital spending has remained below operating cash flow throughout the displayed quarterly series. That gives the business internal funding capacity even when reported earnings are volatile.
The balance sheet is the sharper constraint. Cash and short-term investments are small beside total debt, the company is deeply net indebted, and cash has declined substantially across the reported window. Liquidity ratios also indicate limited short-term balance-sheet slack, while weak returns and a thin net margin leave less room for operating setbacks than the broad product portfolio might suggest.
A simultaneous slowdown in medication use, diagnostic activity, and procedure volumes would reach different parts of BD rather than a narrow product line. If weaker revenue also prevents gross profit from supporting the selling and administrative cost base, the recent operating-profit recovery could unwind quickly while debt obligations remain.
What should you watch next at Becton, Dickinson and Company (BDX)?
Short answer · as of
The next earnings report is expected on Feb 8, 2027.
Research dated 2026-09-12 (results through Q3 FY2026; Q4 FY2026 not covered).
The next report needs to preserve the latest relationship between sales and operating profit. Revenue growth without sustained gross profit or with renewed pressure from selling and administrative expense would weaken the recovery; continued profit expansion on modest sales movement would support it.
Cash conversion deserves equal attention. Operating cash flow must continue to cover capital spending, but the more demanding test is whether the cash balance stabilizes while debt remains elevated. The scheduled earnings release also provides a fresh check against revenue and per-share expectations after a history of steadier earnings beats than revenue beats.
Beyond the immediate report, consensus estimates imply rising revenue and per-share earnings across the forecast horizon. Progress toward that path should appear in segment demand and consolidated margins, not merely in adjusted per-share results.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Becton, Dickinson and Company compare with its peers?
Short answer
Becton, Dickinson and Company's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12 (results through Q3 FY2026; Q4 FY2026 not covered).
BD differs from a narrowly focused medical-device company because its results are not a pure wager on elective procedures, laboratory equipment, or drug delivery alone. Medical supplies and medication systems sit beside diagnostics, research tools, and interventional products, with Medical contributing the largest share but not defining the whole company.
That breadth spreads demand across providers, laboratories, researchers, and pharmaceutical firms, yet it also makes consolidated revenue harder to interpret from an industry label. A sales change can reflect shifts in routine clinical consumption, diagnostic workloads, equipment demand, or procedure activity, and those streams need not move together.
| Company | Price | Market value | Score |
|---|---|---|---|
| $925.70 Nov 20, 2026 | $58.2B | 96 5-pillar Nov 18, 2026 | |
| $676.21 Nov 20, 2026 | $53.3B | 96 5-pillar Nov 18, 2026 | |
| $236.88 Nov 19, 2026 | $33.3B | 95 5-pillar Nov 18, 2026 | |
| $407.24 Nov 19, 2026 | $141B | 94 5-pillar Nov 18, 2026 | |
| $103.88 Nov 19, 2026 | $59.7B | 93 5-pillar Nov 18, 2026 | |
| $396.69 Nov 19, 2026 | $27.6B | 92 5-pillar Nov 18, 2026 | |
| $272.93 Nov 20, 2026 | $63.1B | 88 5-pillar Nov 18, 2026 | |
| $74.31 Nov 20, 2026 | $35.7B | 80 5-pillar Nov 18, 2026 | |
| $140.34 Nov 19, 2026 | $8.90B | 77 5-pillar Nov 18, 2026 | |
| $9.05 Nov 19, 2026 | $39.7B | 75 5-pillar Nov 18, 2026 | |
| $37.84 Nov 19, 2026 | $49.8B | 72 5-pillar Nov 18, 2026 | |
| $170.29 Nov 19, 2026 | $10.9B | 71 5-pillar Nov 18, 2026 | |
| Becton, Dickinson and Company (BDX) — this page | $212.78 | $58.0B | 68 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $165.00 – $242.00
- Consensus target
- $200.57
- Median target
- $190.00
Consensus record · Captured .
Measured against a quoted price of $212.78 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 30
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 12
- Other transactions
- 18
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BDX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported BDX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
BDX Healthcare Stock FAQ
Research dated 2026-09-12 (results through Q3 FY2026; Q4 FY2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is BD Medical different from BD Life Sciences?
BD Medical concentrates on medication delivery and management, including injection, infusion, vascular access, dispensing, and pharmaceutical delivery products. BD Life Sciences is oriented toward specimen collection, microbiology, molecular diagnostics, cytology, and cell-analysis workflows.
How do BD infusion systems and dispensing products fit together?
They address connected stages of medication management, from preparation and storage through delivery to the patient. This makes BD Medical broader than a standalone catheter or syringe business.
Why does procedure activity matter to BD Interventional?
BD Interventional supplies products used in hernia repair, biosurgery, infection prevention, peripheral intervention, urology, and critical care. Changes in surgical and interventional workloads can therefore affect this segment differently from routine injection or laboratory demand.
Have BD earnings beats matched the stability of reported profit?
Per-share results have exceeded estimates throughout the displayed earnings history, but reported net income has been less stable and included a recent loss before rebounding. Estimate performance and statutory profitability are therefore giving different signals about operating consistency.
What is the BDX stock price today?
The last price recorded for Becton, Dickinson and Company (BDX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BDX price target?
The analyst consensus price target for Becton, Dickinson and Company (BDX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 43 figures on this page — 1 from SEC filings and earnings calls, 36 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com